title: A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
abstract: OBJECTIVE
  Few controlled studies have addressed the issue of effective medical treatment for nonalcoholic fatty liver disease (NAFLD). We herein assessed the effect of orlistat in patients with NAFLD.
  
  
  METHODS
  We performed a randomized, double-blind, placebo-controlled study on 52 patients with NAFLD diagnosed by ultrasound (US) and confirmed by liver biopsy (40 patients). The patients were randomized to receive either orlistat (120 mg 3 times daily for 6 months) or placebo. All patients participated in an identical behavioral weight loss program. All patients underwent monthly evaluation by abdominal US; liver enzyme levels, lipid profiles, insulin levels, and anthropometric parameters were monitored, and all patients underwent nutritional follow-up evaluation. Twenty-two patients underwent a second liver biopsy examination at the end of the study.
  
  
  RESULTS
  Fifty-two patients were recruited and 44 (mean age, 47.7 y; mean body mass index, 33) completed the study. Serum glucose and insulin levels (P<.03) were significantly higher in the orlistat group, which also presented a higher degree of fibrosis. Body mass index was reduced significantly in each group, with a nonsignificant difference between the groups. Serum alanine transaminase (ALT) levels decreased significantly in both groups, with an almost 2-fold reduction in the orlistat group (48% vs 26.4%). There was a statistically significant reversal of fatty liver by US only in the orlistat group (P<.05).
  
  
  CONCLUSIONS
  Orlistat improves serum ALT levels and steatosis on US in NAFLD patients, beyond its effect on weight reduction.
authors.affiliation: The Liver Unit, Department of Gastroenterology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Shira
authors.initials: S
authors.lastname: Zelber-Sagi
authors.forename: Ada
authors.initials: A
authors.lastname: Kessler
authors.forename: Eli
authors.initials: E
authors.lastname: Brazowsky
authors.forename: Muriel
authors.initials: M
authors.lastname: Webb
authors.forename: Yoav
authors.initials: Y
authors.lastname: Lurie
authors.forename: Moshe
authors.initials: M
authors.lastname: Santo
authors.forename: Moshe
authors.initials: M
authors.lastname: Leshno
authors.forename: Laurence
authors.initials: L
authors.lastname: Blendis
authors.forename: Zamir
authors.initials: Z
authors.lastname: Halpern
authors.forename: Ran
authors.initials: R
authors.lastname: Oren
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001707:Biopsy, Needle; D015992:Body Mass Index; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005234:Fatty Liver / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D007783:Lactones / Q000627:therapeutic use*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D000077403:Orlistat; D011336:Probability; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D018608:Ultrasonography, Doppler; D015431:Weight Loss / Q000187:drug effects
chemical_list: D019440:Anti-Obesity Agents; D007783:Lactones; D000077403:Orlistat